Policies and guidelines

In most of our markets, GSK payment terms are calculated from the date the invoice is received by GSK, not from the invoice date. We expect our suppliers to meet our standards, but we also have a responsibility to support them by paying on time. We have put in place an exception to our standard payment terms for small and medium sized companies in the UK, and small suppliers in the USA.

If you are a UK company which is a micro, small or medium sized enterprise, GSK will apply these preferential terms(60+5 term) when you are registered as a supplier to us. Please email us if this is the case and we will update your payment terms.

If you are a US company which meets the small business size standards, GSK will offer you preferential payment terms(60+5 term). Please email us so that we can confirm your organisation meets the criteria and update your payment terms.

Typical payment terms applicable to exceptional cases listed above

Patients are at the heart of everything we do. We collect HSI to help us evaluate the safe use of our medicines. It’s the right thing to do and it’s required of us to protect the patients we serve. HSI from human subject research is reported as described in the study protocol.

Human safety information (HSI) is defined as information relating to human health and/or well-being following exposure to GSK products, such as Adverse Event (AE) information, including:

• Any unintended sign (including an abnormal laboratory finding) symptom or disease (new or exacerbated)
• Failure to produce expected benefits (i.e. lack of efficacy)
• Off-label use
• Medication errors or misuse, including drug overdose, whether accidental or intentional
• Drug abuse or effects of drug withdrawal
• Occupational exposure
• Patients taking GSK products whilst pregnant or breastfeeding
• Paternal exposure to a GSK product before and during pregnancy
• Transmission of an infectious agent via a medicinal product
• Safety information received as part of a product quality complaint
• Drug interaction
• Unexpected therapeutic benefits (i.e. an unexpected improvement in a concurrent condition other than the one being treated)
• Suspected adverse reactions associated with a suspected or confirmed falsified medicinal product or with a quality defect of a medicinal product

An Adverse Event (AE) is defined as any untoward medical occurrence in a patient of clinical investigation subject or a consumer, temporally associated with the use of a GSK Product, whether or not considered related to the product.

The GSK policy on promotional and non-promotional external interactions is aligned with our corporate purpose, strategy, and culture.

The policy provides principles for promotional and non-promotional external interactions so that these interactions:

• Support external understanding and appropriate use of GSK products for the benefit of individual patients and populations
• Are transparent, appropriate, ethical, and comply with relevant laws, regulations and industry codes